Halinder S Mangat1,2, Xian Wu3, Linda M Gerber3, Justin T Schwarz2,4, Malik Fakhar1, Santosh B Murthy1, Philip E Stieg2, Jamshid Ghajar5,6, Roger Härtl2. 1. Department of Neurology, Weill Cornell Medicine, New York, New York. 2. Department of Neurological Surgery, Weill Cornell Brain and Spine Institute, Weill Cornell Medicine, New York, New York. 3. Department of Healthcare Policy & Research, Weill Cornell Medicine, New York, New York. 4. NewYork-Presbyterian Hospital, New York, New York. 5. Department of Neurological Surgery, Stanford University, Palo Alto, California. 6. Brain Trauma Foundation, New York, New York.
Abstract
BACKGROUND: Hypertonic saline (HTS) and mannitol are effective in reducing intracranial pressure (ICP) after severe traumatic brain injury (TBI). However, their simultaneous effect on the cerebral perfusion pressure (CPP) and ICP has not been studied rigorously. OBJECTIVE: To determine the difference in effects of HTS and mannitol on the combined burden of high ICP and low CPP in patients with severe TBI. METHODS: We performed a case-control study using prospectively collected data from the New York State TBI-trac® database (Brain Trauma Foundation, New York, New York). Patients who received only 1 hyperosmotic agent, either mannitol or HTS for raised ICP, were included. Patients in the 2 groups were matched (1:1 and 1:2) for factors associated with 2-wk mortality: age, Glasgow Coma Scale score, pupillary reactivity, hypotension, abnormal computed tomography scans, and craniotomy. Primary endpoint was the combined burden of ICPhigh (> 25 mm Hg) and CPPlow (< 60 mm Hg). RESULTS: There were 25 matched pairs for 1:1 comparison and 24 HTS patients matched to 48 mannitol patients in 1:2 comparisons. Cumulative median osmolar doses in the 2 groups were similar. In patients treated with HTS compared to mannitol, total number of days (0.6 ± 0.8 vs 2.4 ± 2.3 d, P < .01), percentage of days with (8.8 ± 10.6 vs 28.1 ± 26.9%, P < .01), and the total duration of ICPhigh + CPPlow (11.12 ± 14.11 vs 30.56 ± 31.89 h, P = .01) were significantly lower. These results were replicated in the 1:2 match comparisons. CONCLUSION: HTS bolus therapy appears to be superior to mannitol in reduction of the combined burden of intracranial hypertension and associated hypoperfusion in severe TBI patients.
BACKGROUND:Hypertonic saline (HTS) and mannitol are effective in reducing intracranial pressure (ICP) after severe traumatic brain injury (TBI). However, their simultaneous effect on the cerebral perfusion pressure (CPP) and ICP has not been studied rigorously. OBJECTIVE: To determine the difference in effects of HTS and mannitol on the combined burden of high ICP and low CPP in patients with severe TBI. METHODS: We performed a case-control study using prospectively collected data from the New York State TBI-trac® database (Brain Trauma Foundation, New York, New York). Patients who received only 1 hyperosmotic agent, either mannitol or HTS for raised ICP, were included. Patients in the 2 groups were matched (1:1 and 1:2) for factors associated with 2-wk mortality: age, Glasgow Coma Scale score, pupillary reactivity, hypotension, abnormal computed tomography scans, and craniotomy. Primary endpoint was the combined burden of ICPhigh (> 25 mm Hg) and CPPlow (< 60 mm Hg). RESULTS: There were 25 matched pairs for 1:1 comparison and 24 HTSpatients matched to 48 mannitolpatients in 1:2 comparisons. Cumulative median osmolar doses in the 2 groups were similar. In patients treated with HTS compared to mannitol, total number of days (0.6 ± 0.8 vs 2.4 ± 2.3 d, P < .01), percentage of days with (8.8 ± 10.6 vs 28.1 ± 26.9%, P < .01), and the total duration of ICPhigh + CPPlow (11.12 ± 14.11 vs 30.56 ± 31.89 h, P = .01) were significantly lower. These results were replicated in the 1:2 match comparisons. CONCLUSION:HTS bolus therapy appears to be superior to mannitol in reduction of the combined burden of intracranial hypertension and associated hypoperfusion in severe TBIpatients.
Authors: Susan L Bratton; Randall M Chestnut; Jamshid Ghajar; Flora F McConnell Hammond; Odette A Harris; Roger Hartl; Geoffrey T Manley; Andrew Nemecek; David W Newell; Guy Rosenthal; Joost Schouten; Lori Shutter; Shelly D Timmons; Jamie S Ullman; Walter Videtta; Jack E Wilberger; David W Wright Journal: J Neurotrauma Date: 2007 Impact factor: 5.269
Authors: Kevin N Sheth; Deborah M Stein; Bizhan Aarabi; Peter Hu; Joseph A Kufera; Thomas M Scalea; Daniel F Hanley Journal: Neurocrit Care Date: 2013-02 Impact factor: 3.210
Authors: C S Robertson; A B Valadka; H J Hannay; C F Contant; S P Gopinath; M Cormio; M Uzura; R G Grossman Journal: Crit Care Med Date: 1999-10 Impact factor: 7.598
Authors: Randall M Chesnut; Nancy Temkin; Nancy Carney; Sureyya Dikmen; Carlos Rondina; Walter Videtta; Gustavo Petroni; Silvia Lujan; Jim Pridgeon; Jason Barber; Joan Machamer; Kelley Chaddock; Juanita M Celix; Marianna Cherner; Terence Hendrix Journal: N Engl J Med Date: 2012-12-12 Impact factor: 91.245
Authors: M Oddo; J M Levine; S Frangos; E Carrera; E Maloney-Wilensky; J L Pascual; W A Kofke; S A Mayer; P D LeRoux Journal: J Neurol Neurosurg Psychiatry Date: 2009-03-16 Impact factor: 10.154
Authors: Renaud Vialet; Jacques Albanèse; Laurent Thomachot; François Antonini; Aurélie Bourgouin; Bernard Alliez; Claude Martin Journal: Crit Care Med Date: 2003-06 Impact factor: 7.598
Authors: Antoine Roquilly; Sigismond Lasocki; Jean Denis Moyer; Olivier Huet; Pierre François Perrigault; Claire Dahyot-Fizelier; Philippe Seguin; Tarek Sharshar; Thomas Geeraerts; Francis Remerand; Fanny Feuillet; Karim Asehnoune Journal: BMJ Open Date: 2017-09-24 Impact factor: 2.692
Authors: Aaron M Cook; G Morgan Jones; Gregory W J Hawryluk; Patrick Mailloux; Diane McLaughlin; Alexander Papangelou; Sophie Samuel; Sheri Tokumaru; Chitra Venkatasubramanian; Christopher Zacko; Lara L Zimmermann; Karen Hirsch; Lori Shutter Journal: Neurocrit Care Date: 2020-06 Impact factor: 3.210